R&D News | pharmaphorum

News

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.

News

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.

News

Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.

News

The FDA says it will review clinical trials that send US citizens' cells to 'hostile countries' as the agency's leadership in this area is sidelined.

News

The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.

News

Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.